Literature DB >> 17852891

First detection of Dobrava hantavirus from a patient with severe haemorrhagic fever with renal syndrome by SYBR Green-based real time RT-PCR.

Ferenc Jakab1, Judit Sebok, Emoke Ferenczi, Gyozo Horváth, György Szucs.   

Abstract

Dobrava hantavirus (DOBV) infection was diagnosed in a previously healthy 46-y-old hunter suffering from severe haemorrhagic fever with renal syndrome (HFRS). Specific IgM antibodies against DOBV were identified by an immunofluorescence assay, while viral nucleic acid was detected by the molecular method, confirming the diagnosis. Our results reveal an existing risk of DOBV transmission to humans in Hungary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17852891     DOI: 10.1080/00365540701387072

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

1.  Molecular diagnostics of hemorrhagic fever with renal syndrome during a Dobrava virus infection outbreak in the European part of Russia.

Authors:  Tamara K Dzagurova; Boris Klempa; Evgeniy A Tkachenko; Galina P Slyusareva; Vyacheslav G Morozov; Brita Auste; Detlev H Kruger
Journal:  J Clin Microbiol       Date:  2009-10-14       Impact factor: 5.948

2.  Genetic detection of dobrava/belgrade virus, bulgaria.

Authors:  Anna Papa; Iva Christova
Journal:  Emerg Infect Dis       Date:  2011-02       Impact factor: 6.883

3.  Development of a one-step SYBR Green I real-time RT-PCR assay for the detection and quantitation of Araraquara and Rio Mamore hantavirus.

Authors:  Alex Martins Machado; William Marciel de Souza; Michelly de Pádua; Aline Rafaela da Silva Rodrigues Machado; Luiz Tadeu Moraes Figueiredo
Journal:  Viruses       Date:  2013-09-19       Impact factor: 5.048

Review 4.  Complex evolution and epidemiology of Dobrava-Belgrade hantavirus: definition of genotypes and their characteristics.

Authors:  Boris Klempa; Tatjana Avsic-Zupanc; Jan Clement; Tamara K Dzagurova; Heikki Henttonen; Paul Heyman; Ferenc Jakab; Detlev H Kruger; Piet Maes; Anna Papa; Evgeniy A Tkachenko; Rainer G Ulrich; Olli Vapalahti; Antti Vaheri
Journal:  Arch Virol       Date:  2012-10-23       Impact factor: 2.574

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.